机构：[1]Department of Pathology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Level 6, Building 6, Shanghai 200050, China[2]Discipline of Pathology, School of Medical Sciences and Bosch Institute, Charles Perkins Centre, The University of Sydney, Rm 4211 West, D17, Sydney, NSW 2006, Australia
Colorectal cancer (CRC) is a leading cause of cancer-related death, partly due to a lack of reliable biomarkers for early diagnosis. To improve the outcome of CRC, it is critical to provide diagnosis at an early stage using promising sensitive/specific marker(s). Using immunohistochemistry and histopathology, IL-38 expression was determined in tissue arrays of CRC with different TNM status and depth of tumour invasion. Data were compared to IL-38 in adjacent non-cancer tissue and correlated with demographic information, including survival. A substantial reduction of IL-38 was detected in the CRC tissue compared to adjacent non-cancer colonic tissue. IL-38 correlated with the extent of tumour differentiation (P < 0.0001); CRC location in the left side of the colon (P < 0.05), and smaller tumour size (<= 5 cm; P < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated both high specificity and high sensitivity of IL-38 for the diagnosis of CRC [area under the curve (AUC) = 0.89)]. By sub-group analysis, AUC of IL-38 for the diagnosis of CRC was higher in poorly differentiated, right-sided CRC or tumour size > 5 cm (all AUC > 0.9). Significantly, longer survival was observed for the IL-38(high) versus the IL-38(low) groups in CRC patients (P = 0.04). Survival was also longer for IL-38(high) patients with lymph node metastasis (P = 0.01) and TNM stage III-IV (P = 0.02). Multivariate analysis demonstrated that IL-38 (P = 0.05) and tumour invasion depth (P = 0.04) were independent factors for survival. High IL38 in CRC is an independent prognostic factor for the longer survival of CRC patients. IL-38 signalling may constitute a therapeutic target in CRC.
基金：
Shanghai Jiaotong University Medical Professional Cross Fund; Joint Research Initiative Grant from Shanghai Jiaotong University, China; Natural Science Foundation of Shanghai, ChinaNatural Science Foundation of Shanghai [16ZR1432600]; School of Medical Sciences, The University of Sydney Small Equipment Grant; SJTU Research Project grant, The University of Sydney 2019
第一作者机构：[1]Department of Pathology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Level 6, Building 6, Shanghai 200050, China[2]Discipline of Pathology, School of Medical Sciences and Bosch Institute, Charles Perkins Centre, The University of Sydney, Rm 4211 West, D17, Sydney, NSW 2006, Australia
通讯作者：
通讯机构：[1]Department of Pathology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Level 6, Building 6, Shanghai 200050, China[2]Discipline of Pathology, School of Medical Sciences and Bosch Institute, Charles Perkins Centre, The University of Sydney, Rm 4211 West, D17, Sydney, NSW 2006, Australia
推荐引用方式(GB/T 7714)：
Chen Feier,Zhang Feng,Tan Zhenyu,et al.Interleukin-38 in colorectal cancer: a potential role in precision medicine[J].CANCER IMMUNOLOGY IMMUNOTHERAPY.2020,69(1):69-79.doi:10.1007/s00262-019-02440-7.
APA：
Chen, Feier,Zhang, Feng,Tan, Zhenyu,Hambly, Brett D.,Bao, Shisan&Tao, Kun.(2020).Interleukin-38 in colorectal cancer: a potential role in precision medicine.CANCER IMMUNOLOGY IMMUNOTHERAPY,69,(1)
MLA：
Chen, Feier,et al."Interleukin-38 in colorectal cancer: a potential role in precision medicine".CANCER IMMUNOLOGY IMMUNOTHERAPY 69..1(2020):69-79
